A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine

• DOI: 10.1016/j.vaccine.2009.01.116
• Publication Date: 2009-02-03T09:56:50Z
• Authors: Rebecca J. Cox; Abdullah S. Madhun; Solveig Hauge; Haakon Sjursen; Diane Major; Mirjam Kuhne; Katja Höschler; Melanie Saville; Frederick R. Vogel; Wendy Barclay; Isabella Donatelli; Maria Zambon; John Wood; Lars R. Haaheim
• Keywords: Adult; Male; 0301 basic medicine; Aluminum Hydroxide; Hemagglutination Inhibition Tests; Antibodies, Viral; Vaccines, Attenuated; Immunoglobulin A; 3. Good health; Young Adult; 03 medical and health sciences; Adjuvants, Immunologic; Influenza A virus; Influenza Vaccines; Neutralization Tests; Immunoglobulin G; Antibody Formation; Influenza, Human; Humans; Interleukin-2; Female

Avian influenza H7 viruses have transmitted from poultry to man causing human illness and fatality, highlighting the need for pandemic preparedness against this subtype. We have developed and tested the first cell-based human vaccine against H7 avian influenza virus in a phase I clinical trial. Sixty healthy volunteers were intramuscularly vaccinated with two doses of split H7N1 virus vaccine containing 12 microg or 24 microg haemagglutinin alone or with aluminium hydroxide adjuvant (300 microg or 600 microg, respectively). The vaccine was well tolerated in all subjects and no serious adverse events occurred. The vaccine elicited low haemagglutination inhibition and microneutralisation titres, although the addition of aluminium adjuvant augmented the antibody response. We found a higher number of antibody secreting cells and an association with IL-2 production in subjects with antibody response. In conclusion, our study shows that producing effective H7 pandemic vaccines is as challenging as has been observed for H5 vaccines.